

Monoclonal Anti-SARS Coronavirus/SARS-Related Coronavirus 2 Nucleocapsid Protein (produced *in vitro*)

Catalog No. NR-53794

Sino Biological Catalog No. 40143-R004

For research use only. Not for use in humans.

Contributor and Manufacturer:

Sino Biological, Wayne, Pennsylvania, USA

Product Description:

Antibody Class: IgG

Clone: 004

NR-53794 is a recombinant monoclonal rabbit antibody, prepared against the severe acute respiratory syndrome coronavirus (SARS-CoV) nucleocapsid (N) protein (Sino Biological 40143-V08B), that was expressed from HEK293 cells and purified.¹

Material Provided:

Each vial of NR-53794 contains approximately 50 µL of monoclonal antibody in phosphate buffered saline (PBS). The concentration, expressed as mg per mL, is shown on the Certificate of Analysis.

Packaging/Storage:

NR-53794 was packaged aseptically in screw-capped plastic vials and is provided frozen on dry ice. The product should be stored at -20°C to -80°C immediately upon arrival. NR-53794 can be stored at 2°C to 8°C for one month without detectable loss of activity. Freeze-thaw cycles should be avoided.

Functional Activity:

NR-53794 is specific to the SARS-CoV N protein as shown in ELISA and western blot analysis (Figure 1), with cross reactivity to the N protein from SARS-CoV-2 (BEI Resources NR-53797; Sino Biological 40588-V08B). No cross reactivity was observed in ELISA with N proteins from MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-HKU1 (isolate N5) or HCoV-OC43.¹

Citation:

Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-SARS Coronavirus/SARS-Related Coronavirus 2 Nucleocapsid Protein (produced *in vitro*), NR-53794.”

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 6th ed. Washington, DC: U.S. Government Printing Office, 2020; see

www.cdc.gov/biosafety/publications/bmbL5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.


References:

1. Lu, Z., Personal Communication.

ATCC® is a trademark of the American Type Culture Collection.



Figure 1: Representative Anti-SARS-CoV-2 Western Blot



Lane 1: SARS-CoV Nucleocapsid (30 ng)
Lane 2: SARS-CoV Nucleocapsid (5 ng)
Lane 3: SARS-CoV-2 Nucleocapsid (30 ng)
Lane 4: SARS-CoV-2 Nucleocapsid (5 ng)